Canepa Healthcare, LLC (“Canepa Healthcare”) is a Securities and Exchange Commission (SEC)-registered investment advisory firm with expertise in global healthcare sector advisory. Canepa Healthcare seeks to identify attractive investment opportunities in companies participating in the global healthcare industry.
Canepa Healthcare serves as the discretionary advisor to its main client, the Canepa Advanced Healthcare Fund, L.P. (“Canepa Advanced Healthcare Fund”). Canepa Healthcare may also provide non-discretionary investment advisory services to other clients. The Canepa Advanced Healthcare Fund is a private investment growth fund that aims to achieve long-term capital appreciation through equity investments primarily in non-public companies that operate in the medical technology (e.g., medical and surgical devices, supplies, and diagnostics) space. It is focused on companies with commercialized products that are in need of growth capital in order to achieve profitability.
Canepa Healthcare has offices in New York and Miami.
The Canepa Advanced Healthcare Fund, Canepa Healthcare’s primary client, focuses on opportunities within the medical technology sector that meet four main criteria:
Stage of investment
The investment objective of the Canepa Advanced Healthcare Fund is to identify healthcare companies with products in the growth stage that have either achieved regulatory clearance or are approaching regulatory approval (where applicable). The fund targets those healthcare companies that can achieve rapid growth for the next 3-5 years.
The Canepa Advanced Healthcare Fund seeks to invest $5m-$20m into companies with enterprise values of $20m-$200m. The fund is flexible with respect to control versus minority stakes but will only consider situations where there is an opportunity to add value through its active involvement.
The Canepa Advanced Healthcare Fund focuses less on specific sub-sectors and more on backing world-class teams. However, the fund is currently prioritizing investments in minimally invasive surgery, cardiovascular and trans-catheter technologies, diagnostics, and genomics.
While the Canepa Advanced Healthcare Fund will consider investment opportunities across geographies, it is targeting the US and European healthcare markets.
Cardiva Medical Inc. is a privately held medical device company that is focused on developing and commercializing innovative vascular closure technology. Cardiva’s VASCADE™ Vascular Closure System was approved by the FDA in 2013 and approved for CE Marking in Europe in 2012. VASCADE is a new generation extravascular closure device designed to increase the comfort and safety of vascular closure for patients. VASCADE utilizes a unique delivery system based on a proprietary collapsible disc technology that provides temporary hemostasis during the procedure which eliminates the need for an intravascular component. Secure and rapid hemostasis is achieved with VASCADE by the deployment of a thrombogenic resorbable collagen patch at the arteriotomy of the femoral artery.
Dune Medical Devices was founded in 2002 to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the ability to detect cancer in real time, this technology holds promise for a broad range of diagnostic and therapeutic applications. The company’s first offering, the MarginProbe® System, is now FDA approved and is being used to deliver real-time assessment on excised tissue in breast cancer surgery. A 300-patient randomized study has shown a reduction in re-operation rates by 56% over the standard of care.
Paul Enever is a managing director at Canepa Healthcare. Before joining Canepa Healthcare, Paul was a partner at McKinsey and Company. In his 12 years at McKinsey, he advised leading organizations across the bio-pharma, med-tech, hospital, and healthcare services industries primarily in the U.S. and Europe as well as private equity firms specializing in healthcare. Paul’s work focused on growth strategy, sales and marketing, and licensing and acquisition. Previously, Paul worked within the R&D organization at Sandoz Pharmaceuticals and MIT’s Biotechnology Process Engineering Center.
He sits on the Boards of Directors of Cardiva Medical, Dune Medical Devices, and Standard Molecular.
Paul has a B.S. in chemical engineering from Rensselaer Polytechnic Institute and a Ph.D. in chemical engineering from the University of Minnesota where he studied wound healing and tissue engineering. For his work, Paul was the recipient of both a National Science Foundation Graduate Fellowship and the Whitaker Foundation Graduate Fellowship in Biomedical Engineering.
Alejandro Sanchez is a managing director at Canepa Healthcare. Prior to joining Canepa Healthcare, he was a co-founder and partner of Hermes Growth Partners, where he launched its Telecom, Media, and Technology Fund. Alejandro is a former partner at McKinsey and Company, where he worked in the telecom, media, and technology sectors across a diverse set of geographies, including Venezuela, Chile, Brazil, Russia, Poland, and the United States.
He serves on the Boards of Directors of bioTheranostics, Tryton Medical, Virgin Mobile Latin America, WAU and NoShame.
Alejandro is a systems engineer with an MS in Engineering-Economic Systems from Stanford University.
Adam Lessler is a vice president at Canepa Healthcare. Prior to joining Canepa Healthcare, Adam was an engagement manager at McKinsey & Company, where he served clients across the health care value chain, with a focus on provider growth and M&A/partnership strategy. Previously, Adam completed his internship in emergency medicine at the Hospital of the University of Pennsylvania and worked as an analyst in the Investment Banking Division at Goldman Sachs and as a research assistant in Harvard Medical School’s Department of Health Care Policy.
Adam serves as a board observer at bioTheranostics and TPier, Inc. (formerly known as Tute Genomics).
Adam has a B.A. in economics from Amherst College, an M.B.A. from the Wharton School of the University of Pennsylvania, and an M.D. from the Perelman School of Medicine at the University of Pennsylvania.
Canepa Advanced Healthcare Fund, L.P.
Clarendon House, 2 Church Street
Hamilton HM11, Bermuda